Does the addition of Hydroxychloroquine HCQ and Azithromycin enhance the effect of Ivermectin against Covid 19 infection?

A COMPARATIVE RANDOMIZED CLINICAL TRIAL OF IVERMECTIN VERSUS HYDROXYCHLOROQUINE, IVERMECTIN, AND AZITHROMYCIN(HIA TRIPLE THERAPY) IN COVID- 19 IN NIGERIA.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

PACTR

Registry ID

PACTR202108891693522

Enrollment

Registered

2021-08-19

Start date

2021-05-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid 19

Interventions

Drugs Ivermectin IVM

Ivermectin IVM Hydroxychloroquine HCQ Azithromycin AZT

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Newly diagnosed cases of Covid 19 virologically confirmed

Exclusion criteria

Exclusion criteria: Pregnant Breastfeeding Allergy to drugs

Design outcomes

Primary

Measure	Time frame
Proportion virologically negative by days 2, 5, 14 and 21 in each arm, other virology outcomes	—

Secondary

Measure	Time frame
Effect on Platelet count and inflammatory markers Time to discharge from care. Time to resolution of symptoms. Serious adverse events. SPO2 changes over time	—

Countries

Nigeria

Contacts

Public ContactYahaya Abdullahi Ndanusa

Medical Director

yndanusa@gmail.com+2348170440500

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026